Instylla’s Embrace Hydrogel Embolic System Launched 

January 28, 2026—Instylla, Inc., a developer of resorbable embolics for peripheral vascular embolization, announced the completion of the first commercial procedure using the company’s Embrace hydrogel embolic system (HES).

Interventional oncologist Ripal Gandhi, MD, from Miami Vascular Specialists in Miami, Florida, performed the first procedure.

“Ongoing innovation is fundamental to how we continue to advance interventional radiology,” commented Dr. Gandhi in the Instylla press release. “Our field relies on tools that allow us to treat complex disease with greater precision and procedural confidence.”

Dr. Gandhi continued, “In this case, I was pleased that Embrace HES allowed me to achieve deep, distal penetration into the tumor vascular bed, which helped me tailor the embolization to the patient’s anatomy and treatment goals.”

He added, “It has been encouraging to see how Embrace HES has evolved with a focus on practical ease of use in the clinical setting. I look forward to further experience with this technology as we continue to evaluate how it can best support patient care.”

The press release noted that in August 2025, the company announced FDA premarket approval of the Embrace HES for the embolization of hypervascular tumors in peripheral arteries ≤ 5 mm.

Approval was based on results from the Instylla HES pivotal study, which is a prospective, randomized, multicenter trial evaluating the safety and effectiveness of Embrace HES compared with standard of care (transcatheter arterial embolization and transarterial chemoembolization), stated the company.